Is digoxin a drug of the past? This old drug is still useful, with some caveats

Cleveland Clinic Journal of Medicine

Volumn 73, Issue 9, 2006, Pages 821-834

  Pervaiz, Mohammad Hassan ^a   Dickinson, Michael G ^b   Yamani, Mohamad ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MACROLIDE; METOPROLOL; NEUROHORMONE; PLACEBO; SPIRONOLACTONE;

AGE DISTRIBUTION; ARTICLE; BLOOD VESSEL TONE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIURESIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; INOTROPISM; MORTALITY; PLASMA RENIN ACTIVITY; PRESSORECEPTOR; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYMPATHETIC TONE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ATRIAL FIBRILLATION; CARDIOTONIC AGENTS; DIGOXIN; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 33748642161     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.9.821     Document Type: Article

References (37)

1. Mason D, Braunwald E. Studies on digitalis: effects of ouabain on systemic vascular resistance and venous tone in normal subjects and in patients with heart failure. J Clin Invest 1964; 43:532-543.
2. Hirsch AT, Dzau VJ, Creager MA. Baroreceptor function in congestive heart failure: effect on neurohumoral activation and regional vascular resistance. Circulation 1987, 75:IV36-IV48.
3. Higgins CB, Vatner SF, Eckberg DL, Braunwald E. Alterations in the baroreceptor reflex in conscious dogs with heart failure. J Clin Invest 1972; 51:715-724.
4. Thames MD, Miller BD, Abboud FM. Sensitization of vagal cardiopulmonary baroreflex by chronic digoxin. Am J Physiol 1982; 243:H815-H818.
5. Krum H, Bigger JT Jr, Goldsmith RL. Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995; 25:289-294.
6. Osterziel KJ, Hanlein D, Dietz R. Interactions between the reninangiotensin system and the parasympathetic nervous system in heart failure. J Cardiovasc Pharmacol 1994; 24(suppl 2):S70-S74.
7. Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol 1989; 13:134-142.
8. Covit AB, Schaer GL, Sealley JE, Laragh Cody R. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med 1983; 75:445-447.
9. Ross J Jr Waldhausen JA, Braunwald E. Studies on digitalis. I. Direct Effects on peripheral vascular resistance. J Clin invest 1960; 39:930-936.
10. Katz AI. Renal Na-K-ATPase: its role in tubular sodium and potassium transport Am J Physiol 1982; 242:F207-F219.
11. Nelson JA, Nechay BR. Effects of cardiac glycosides on renal adenosine triphosphatase activity and Na+ reabsorption in dogs. J Pharmacol Exp Ther 1970; 175:727-740.
12. Rocco T, Fang JC. Pharmacologic treatment of heart failure. In: Brunton L, Lazo J, Parker K, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2006:869-809.
13. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993; 22:955-962.
14. Packer M. Gheorghiade M. Young JB et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993; 329:1-7.
15. Ward RE, Gheorghiade M. Young JB, Uretsky B. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardioll 1995; 26:93-101.
16. The Digitalis investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533.
17. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149:209-216.
18. Redfors A. The effect of different digoxin doses on subjective symptoms and physical working capacity in patients with atrial fibrillation. Acta Med Scand 1971; 190:307-320.
19. Khand AU, Rankin AC, Martin W, Taylor J, Gerriniell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003; 42:1944-1951.
20. Sticherling C. Oral H, Honrocks J, et al. Effects of digoxin on acute, atrial fibrillation-induced changes in atrial refractoriness. Circulation 2000; 102:2503-2508.
21. Falk RHI, Knowlton AA. Bernard SA, Gotlieb NE, Battinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Ann Intern Med 1987; 106:503-506.
22. Golzari K Cebul RD, Bahler RC Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy. Ann Intern Med 1996; 125:311-323
23. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
24. Willenheimer R. van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112:2426-2435.
25. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005,46:e1-e82.
26. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87(suppl 6):VI40-VI48.
27. Francis GS. Neurohumoral activation and progression of heart failure: hypothetical and clinical considerations. J Cardiovasc Pharmacol 1998; 32(suppl 1):S16-S21.
28. Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Disfunction. SOLVD Investigators. J Am Coll Cardioll 1994; 23:1410-1420.
29. Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulator in heart failure? Circulation 1991; 84:2181-2186.
30. Adams KF Jr, Gheorghiade M, Uretsky BF, Patterson JH, Schwartz TA, Young JB. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol 2002; 39:946-953.
31. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871-878.
32. Ahmed A. Aban IB, Weaver MT, Aronow WS, Fleg JL Serum digoxin concentration and outcomes in women with heart failure: a bi-directional effect and a possible effect modification by ejection fraction. Eur J Heart Fail 2005; 8:409-419.
33. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27:178-186.
34. Sidwell A, Barday M, Begg E, Moore G. Digoxin therapeutic drug monitoring: an audit and review. N Z Med J 2003; 116:U708.
35. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347:1403-1411.
36. Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group trial. A retrospective analysis. J Am Coll Cardiol 2005; 46.497-504.
37. Young JB. Whither Withering's legacy? Digoxin's role in our contemporary pharmacopeia for heart failure. J Am Coll Cardiol 2005; 46:505-507.